EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway

Keum-Jin Yang, Won Jung Choi iD, Yoon-Kyung Chang iD, Cheol Whee Park, Suk Young Kim, Yu Ah Hong iD

International Journal of Molecular Sciences · 14.02.2023 · 24 (4) · 3807

DOI: 10.3390/ijms24043807 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.02.2023. Verfasst von Keum-Jin Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Institute, Daejeon St. Mary's Hospital, 64, Daeheung-ro, Jung-gu, Daejeon 34943, Republic of Korea. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Xanthine Oxidase. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Catholic Medical Center Research Foundation, Clinical Research Institute of Daejeon St. Mary's Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Xanthine oxidase (XO) is an important source of reactive oxygen species. This study investigated whether XO inhibition exerts renoprotective effects by inhibiting vascular endothelial growth factor (VEGF) and NADPH oxidase (NOX) in diabetic kidney disease (DKD). Febuxostat (5 mg/kg) was administered to streptozotocin (STZ)-treated 8-week-old male C57BL/6 mice via intraperitoneal injection for 8 weeks. The cytoprotective effects, its mechanism of XO inhibition, and usage of high-glucose (HG)-treated cultured human glomerular endothelial cells (GECs) were also investigated. Serum cystatin C, urine albumin/creatinine ratio, and mesangial area expansion were significantly improved in febuxostat-treated DKD mice. Febuxostat reduced serum uric acid, kidney XO levels, and xanthine dehydrogenase levels. Febuxostat suppressed the expression of VEGF mRNA, VEGF receptor (VEGFR)1 and VEGFR3, NOX1, NOX2, and NOX4, and mRNA levels of their catalytic subunits. Febuxostat caused downregulation of Akt phosphorylation, followed by the enhancement of dephosphorylation of transcription factor forkhead box O3a (FoxO3a) and the activation of endothelial nitric oxide synthase (eNOS). In an in vitro study, the antioxidant effects of febuxostat were abolished by a blockade of VEGFR1 or VEGFR3 via NOX-FoxO3a-eNOS signaling in HG-treated cultured human GECs. XO inhibition attenuated DKD by ameliorating oxidative stress through the inhibition of the VEGF/VEGFR axis. This was associated with NOX-FoxO3a-eNOS signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesXanthine OxidaseAnimalsHumansMaleMiceEndothelial CellsFebuxostatMice, Inbred C57BLNADPH OxidasesNitric Oxide Synthase Type IIIOxidative StressRNA, MessengerSignal TransductionUric AcidVascular Endothelial Growth Factor AVascular Endothelial Growth Factors

Stichwörter der Autor:innen

NADPH oxidaseVEGFdiabetic kidney diseaseoxidative stressxanthine oxidase

Substanzen

FebuxostatNADPH OxidasesNitric Oxide Synthase Type IIIRNA, MessengerUric AcidVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsXanthine Oxidase

Autor:innen und Institutionen

  • Clinical Research Institute, Daejeon St. Mary's Hospital, 64, Daeheung-ro, Jung-gu, Daejeon 34943, Republic of Korea.
  • Division of Nephrology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea.

ORCID-Profile: Won Jung Choi, Yoon-Kyung Chang, Yu Ah Hong

Förderung

  • National Research Foundation of Korea
  • Catholic Medical Center Research Foundation
  • Clinical Research Institute of Daejeon St. Mary's Hospital
  • Clinical Research Institute of Daejeon St. Mary’s Hospital

Zitieren

APA

Yang, K. J., Choi, W. J., Chang, Y. K., Park, C. W., Kim, S. Y., & Hong, Y. A. (2023). Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway. International Journal of Molecular Sciences, 24(4), 3807. https://doi.org/10.3390/ijms24043807

Vancouver

Yang KJ, Choi WJ, Chang YK, Park CW, Kim SY, Hong YA. Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway. International Journal of Molecular Sciences. 2023;24(4):3807. doi:10.3390/ijms24043807

BibTeX
@article{Yang2023,
  author = {Yang, Keum-Jin and Choi, Won Jung and Chang, Yoon-Kyung and Park, Cheol Whee and Kim, Suk Young and Hong, Yu Ah},
  title = {Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {4},
  pages = {3807},
  doi = {10.3390/ijms24043807}
}
Kostenlos starten →